CVE:TLT Theralase Technologies (TLT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free TLT Stock Alerts C$0.16 0.00 (0.00%) (As of 02:52 PM ET) Add Compare Share Share Today's RangeC$0.17▼C$0.1750-Day RangeC$0.16▼C$0.2452-Week RangeC$0.16▼C$0.31Volume82,500 shsAverage Volume129,722 shsMarket CapitalizationC$38.80 millionP/E RatioN/ADividend Yield1,757.58%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades Get Theralase Technologies alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Theralase Technologies Stock (CVE:TLT)Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. The company was incorporated in 1989 and is based in Toronto, Canada.Read More TLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLT Stock News HeadlinesApril 24, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Closes $CAN 750,000 Non-Brokered Private PlacementApril 5, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Granted Canadian Cancer Vaccine PatentApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 5, 2024 | finance.yahoo.comTheralase(R) Granted Canadian Cancer Vaccine PatentMarch 26, 2024 | finance.yahoo.comTheralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological AssociationMarch 16, 2024 | theglobeandmail.comClosing Bell: Theralase Technologies Inc flat on Friday (TLT)March 1, 2024 | morningstar.comTheralase Technologies Inc TLTFebruary 12, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's DiseaseApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 12, 2024 | finance.yahoo.comTheralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's DiseaseFebruary 8, 2024 | finance.yahoo.comDr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical StudyFebruary 5, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Closes $CAN 1.2 Million Non-Brokered Private PlacementFebruary 5, 2024 | finance.yahoo.comTheralase(R) Closes $CAN 1.2 Million Non-Brokered Private PlacementJanuary 15, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Provides Update on Phase II Bladder Cancer Clinical StudyDecember 1, 2023 | proactiveinvestors.comTheralase makes positive progress on Phase II study on...Theralase makes positive progress on Phase II study on bladder...November 30, 2023 | proactiveinvestors.comTheralase concludes $1.17M private placement for cancer treatment advancementsNovember 30, 2023 | proactiveinvestors.comTheralase focused on breakthrough designation after positive preliminary study dataNovember 29, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Release's 3Q2023 Interim Financial StatementsNovember 29, 2023 | finance.yahoo.comTheralase Release's 3Q2023 Interim Financial StatementsNovember 29, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Closes $CAN 1.17 Million Non-Brokered Private PlacementNovember 17, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Commences Non-Brokered Private Placement and Termination of Previously Announced FinancingNovember 17, 2023 | finance.yahoo.comTheralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced FinancingOctober 23, 2023 | benzinga.comTheralase(R) Announces Brokered LIFE FinancingOctober 23, 2023 | finance.yahoo.comTheralase(R) Optimizes Phase II Bladder Cancer Clinical StudyOctober 16, 2023 | finance.yahoo.comTheralase(R) Provides Update on Bladder Cancer Clinical StudyOctober 10, 2023 | theglobeandmail.comClosing Bell: Theralase Technologies Inc WT up on Friday (TLT-WT)October 5, 2023 | finance.yahoo.comTheralase(R) Files US Patent for Enhanced ImmunotherapySee More Headlines Receive TLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/25/2024Next Earnings (Estimated)6/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolCVE:TLT CUSIPN/A CIKN/A Webtheralase.com Phone+1-416-6995273FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-168.79% Return on Assets-70.70% Debt Debt-to-Equity Ratio25.07 Current Ratio1.22 Quick Ratio3.40 Sales & Book Value Annual SalesC$1.03 million Price / Sales38.81 Cash FlowC$0.01 per share Price / Cash Flow30.45 Book ValueC$0.01 per share Price / Book17.00Miscellaneous Outstanding Shares235,130,000Free FloatN/AMarket CapC$39.97 million OptionableNot Optionable Beta1.66 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Kristina Hachey CPACFO & DirectorDr. Arkady Mandel DSc.M.D., Ph.D., Chief Scientific Officer & DirectorMr. Roger John Dumoulin-White B.Sc.P.Eng., President, CEO & DirectorMr. David M. Groves B.APresident of World Trade DivisionDr. Terry Ruch DVMEquine Medical ConsultantKey CompetitorsHelius Medical TechnologiesTSE:HSMVentriPoint DiagnosticsCVE:VPTProtech Home MedicalCVE:PHMMedX HealthCVE:MDXAurora SpineCVE:ASGView All CompetitorsInsidersMatthew Thomas PerratonBought 900 shares on 1/4/2024Total: C$176.49 ($0.20/share)View All Insider Transactions TLT Stock Analysis - Frequently Asked Questions How have TLT shares performed in 2024? Theralase Technologies' stock was trading at C$0.18 at the start of the year. Since then, TLT shares have decreased by 2.9% and is now trading at C$0.17. View the best growth stocks for 2024 here. When is Theralase Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our TLT earnings forecast. How were Theralase Technologies' earnings last quarter? Theralase Technologies Inc. (CVE:TLT) posted its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.01) EPS for the quarter. The firm earned $0.36 million during the quarter. Is Theralase Technologies a good dividend stock? Theralase Technologies (CVE:TLT) pays an annual dividend of C$2.90 per share and currently has a dividend yield of 2.03%. What other stocks do shareholders of Theralase Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theralase Technologies investors own include IMRIS (IMRSQ), Cross Timbers Royalty Trust (CRT), Aurora Cannabis (ACB), AGNC Investment (AGNC), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), Ford Motor (F), Gladstone Investment (GAIN) and Heat Biologics (HTBX). How do I buy shares of Theralase Technologies? Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:TLT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe World's First "$20 Trillion Drug?"Behind the MarketsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theralase Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.